Drug Profile


Alternative Names: Adifax; D-fenfluramine; Dextrofenfluramine; Dipondal; IP 001; Isomeride; Obedial; Redux; S 5614

Latest Information Update: 27 Apr 2000

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Servier
  • Class Anorectics; Small molecules
  • Mechanism of Action Serotonin release stimulants; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Obesity

Most Recent Events

  • 27 Apr 2000 Fenfluramine/dexfenfluramine has been withdrawn in Europe
  • 28 Sep 1998 Results of 3 studies looking at the evidence linking anorectics with valvular heart disease have been added to the Adverse Events section ,,,
  • 05 Jun 1998 Launched for Obesity in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top